- Home
- NVGS vs EOLS Comparison
NVGS vs EOLS Comparison
Compare NVGS & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- EOLS
- Stock Information
- Founded
- NVGS 1997
- EOLS 2012
- Country
- NVGS United Kingdom
- EOLS United States
- Employees
- NVGS N/A
- EOLS N/A
- Industry
- NVGS Marine Transportation
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- NVGS Consumer Discretionary
- EOLS Health Care
- Exchange
- NVGS Nasdaq
- EOLS Nasdaq
- Market Cap
- NVGS 957.8M
- EOLS 854.0M
- IPO Year
- NVGS N/A
- EOLS 2018
- Fundamental
- Price
- NVGS $13.22
- EOLS $12.22
- Analyst Decision
- NVGS Strong Buy
- EOLS Strong Buy
- Analyst Count
- NVGS 3
- EOLS 4
- Target Price
- NVGS $22.00
- EOLS $24.67
- AVG Volume (30 Days)
- NVGS 270.7K
- EOLS 693.2K
- Earning Date
- NVGS 03-12-2025
- EOLS 05-06-2025
- Dividend Yield
- NVGS 1.51%
- EOLS N/A
- EPS Growth
- NVGS 8.18
- EOLS N/A
- EPS
- NVGS 1.19
- EOLS N/A
- Revenue
- NVGS $566,679,000.00
- EOLS $266,274,000.00
- Revenue This Year
- NVGS $3.48
- EOLS $35.06
- Revenue Next Year
- NVGS $1.14
- EOLS $33.04
- P/E Ratio
- NVGS $11.08
- EOLS N/A
- Revenue Growth
- NVGS 2.90
- EOLS 31.76
- 52 Week Low
- NVGS $13.05
- EOLS $9.25
- 52 Week High
- NVGS $18.18
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- NVGS 26.50
- EOLS 39.01
- Support Level
- NVGS $13.15
- EOLS $11.59
- Resistance Level
- NVGS $14.47
- EOLS $13.66
- Average True Range (ATR)
- NVGS 0.36
- EOLS 0.53
- MACD
- NVGS -0.00
- EOLS -0.11
- Stochastic Oscillator
- NVGS 11.85
- EOLS 30.43
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture).
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.